| Arsenic | Health-Based | N/A | 0.027 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.024 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.024 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.024 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.024 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.028 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.028 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.028 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.028 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.021 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.021 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.021 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.021 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.017 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Jan 29, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Oct 15, 2022 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| E. COLI | Monitoring | 0 | N/A | Sep 14, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Sep 14, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Sep 14, 2022 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 16, 2022 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 10, 2021 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |